OVID - Latest News

Ovid Therapeutics Inc. (OVID), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $369.3M. Beta to the broader market is 0.18.

The article list below shows the most recent OVID headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent OVID Headlines

Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

globenewswire.com - May 12, 2026

Dosed first participant with OV4071, the first-ever oral potassium-chloride cotransporter 2 (KCC2) direct activator, in May 2026 in a Phase 1 study wi

AtaiBeckley wins OVID Health Silver Award for patient partnership in psychedelic trials

proactiveinvestors.com - Apr 27, 2026

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) said on Monday it had received the Silver Award in OVID Health's 2026 Patient Participant Index, recognizin

Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript

seekingalpha.com - Apr 14, 2026

Ovid Therapeutics Inc.

Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14

globenewswire.com - Apr 8, 2026

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines f

Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of “Buy” from Brokerages

defenseworld.net - Mar 26, 2026

Shares of Ovid Therapeutics (NASDAQ: OVID - Get Free Report) have received an average rating of "Buy" from the nine research firms that are currently

How News Affects OVID Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track OVID's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked OVID news questions

What is the latest OVID news headline?

The most recent OVID headline (May 12, 2026) is "Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the OVID news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What OVID news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual OVID options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.